Apr 21, 2020
Multiple Sclerosis Drugs Industry Assessment 2020: Immunomodulators, Immunosuppressants, Interferons and Others
Feb 06, 2020
EMD Serono Receives Positive Recommendation for MAVENCLAD® (cladribine tablets) for the treatment of Relapsing-Remitting Multiple Sclerosis from the Institut national d'excellence en santé et en services sociaux (INESSS)
Aug 28, 2019
EMD Serono to Showcase Scientific Leadership at ECTRIMS 2019 with New Data Across Multiple Sclerosis Medicines
Apr 30, 2019
EMD Serono to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019
Apr 08, 2019
MAVENCLAD® (Cladribine) Tablets Now Covered by Express Scripts
Mar 29, 2019
FDA approves new oral treatment for multiple sclerosis
Mar 29, 2019
FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis
Mar 26, 2019
FDA approves new oral drug to treat multiple sclerosis
Feb 28, 2019
EMD Serono to Present Multiple Sclerosis Data on Cladribine Tablets and Evobrutinib at ACTRIMS 2019
Oct 10, 2018
Up to 10-Years of Follow-up Data Reaffirm Safety Profile of Investigational Cladribine Tablets
Oct 08, 2018
Novartis announces FDA filing acceptance of siponimod (BAF312), the first and only oral drug shown to delay disability progression in typical SPMS patients
Oct 02, 2018
Accelerated Cure Project Announces Collaboration with EMD Serono to Advance Patient-Focused Drug Development in Multiple Sclerosis
Sep 06, 2018
PharmaPoint: Multiple Sclerosis (MS) Market Global Drug Forecast and Market Analysis to 2026- ReportsnReports
Jul 30, 2018
FDA Accepts File for Cladribine Tablets as Potential Treatment for Relapsing Forms of Multiple Sclerosis
Jun 26, 2018
A Paradigm Shift in Disease-Modifying Therapy Treatment Rates for Progressive Forms of Multiple Sclerosis Largely Dependent Upon Genentech's Ocrevus Prescribing Patterns
May 29, 2018
EMD Serono to Present MS Data and Debut New Patient Resources at CMSC 2018
Mar 22, 2018
Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS
Feb 26, 2018
Mavenclad (Cladribine Tablets) Receives First Approval in Latin America
Feb 06, 2018
British Columbia includes (Pr)LEMTRADA® (alemtuzumab) on provincial drug program for eligible patients
Feb 02, 2018
Clene Nanomedicine Announces Preclinical Results of A Novel Gold Nanocrystal Remyelinating Treatment for Multiple Sclerosis at ACTRIMS Forum Annual Meeting